专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08084457B2 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases 有权
标题翻译：药物活性的4,6-二取代氨基嘧啶衍生物作为蛋白激酶的调节剂
公开(公告)号：US08084457B2
公开(公告)日：2011-12-27
申请号：US10572043
申请日：2004-09-15
申请人： Axel Choidas , Alexander Backes , Matt Cotten , Ola Engkvist , Beatrice Felber , Achim Freisleben , Klaus Godl , Zoltán Greff , Peter Habenberger , Doris Hafenbradl , Christian Hartung , Thomas Herget , Edmund Hoppe , Bert Klebl , Andrea Missio , Gerhard Müller , Wilfried Schwab , Birgit Zech , Jose Bravo , John Harris , Joelle Le , Jackie Macritchie , Vladimir Savic , Brad Sherborne , Don Simpson
发明人： Axel Choidas , Alexander Backes , Matt Cotten , Ola Engkvist , Beatrice Felber , Achim Freisleben , Klaus Godl , Zoltán Greff , Peter Habenberger , Doris Hafenbradl , Christian Hartung , Thomas Herget , Edmund Hoppe , Bert Klebl , Andrea Missio , Gerhard Müller , Wilfried Schwab , Birgit Zech , Jose Bravo , John Harris , Joelle Le , Jackie Macritchie , Vladimir Savic , Brad Sherborne , Don Simpson
IPC分类号： A01N43/54 , C07D239/42 , C07D401/04 , C07D239/00 , C07D239/02
CPC分类号： C04B35/632 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要： The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.
摘要翻译：本发明涉及4,6-二取代的氨基嘧啶衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，朊病毒疾病，免疫学疾病，自身免疫疾病，双相和临床疾病，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经变性疾病和中风，以及含有所述4,6-二取代氨基嘧啶衍生物和 /或其药学上可接受的盐。此外，本发明涉及所述4,6-二取代氨基嘧啶衍生物作为蛋白激酶的抑制剂和包含至少一种固定化形式的所述4,6-二取代氨基嘧啶衍生物的介质和使用所述培养基用于富集，纯化和/或消除与固定的4,6-二取代氨基嘧啶衍生物结合的核苷酸结合蛋白。

2. 发明申请

US20070191344A1 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases 有权
标题翻译：药物活性的4,6-二取代氨基嘧啶衍生物作为蛋白激酶的调节剂
公开(公告)号：US20070191344A1
公开(公告)日：2007-08-16
申请号：US10572043
申请日：2004-09-15
申请人： Axel Choidas , Alexander Backes , Matt Cotten , Ola Engkvist , Beatrice Felber , Achim Freisleben , Klaus Godl , Zoltan Greff , Peter Habenberger , Doris Hafenbradl , Christian Hartung , Thomas Herget , Edmund Hoppe , Bert Klebl , Andrea Missio , Gerhard Muller , Wilfried Schwab , Birgit Zech , Jose Bravo , John Harris , Joelle Le , Jackie Macritchie , Vladimir Savic , Brad Sherborne , Don Simpson
发明人： Axel Choidas , Alexander Backes , Matt Cotten , Ola Engkvist , Beatrice Felber , Achim Freisleben , Klaus Godl , Zoltan Greff , Peter Habenberger , Doris Hafenbradl , Christian Hartung , Thomas Herget , Edmund Hoppe , Bert Klebl , Andrea Missio , Gerhard Muller , Wilfried Schwab , Birgit Zech , Jose Bravo , John Harris , Joelle Le , Jackie Macritchie , Vladimir Savic , Brad Sherborne , Don Simpson
IPC分类号： A61K31/55 , A61K31/506 , C07D403/02
CPC分类号： C04B35/632 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要： The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.
摘要翻译：本发明涉及4,6-二取代的氨基嘧啶衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，朊病毒疾病，免疫学疾病，自身免疫疾病，双相和临床疾病，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经变性疾病和中风，以及含有所述4,6-二取代氨基嘧啶衍生物和 /或其药学上可接受的盐。此外，本发明涉及所述4,6-二取代氨基嘧啶衍生物作为蛋白激酶的抑制剂和包含至少一种固定化形式的所述4,6-二取代氨基嘧啶衍生物的介质和使用所述培养基用于富集，纯化和/或消除与固定的4,6-二取代氨基嘧啶衍生物结合的核苷酸结合蛋白。

3. 发明申请

US20140287454A1 SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS 审中-公开
标题翻译：选择性CDK9抑制剂的缺点
公开(公告)号：US20140287454A1
公开(公告)日：2014-09-25
申请号：US14240315
申请日：2012-08-22
申请人： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
发明人： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
IPC分类号： G01N33/50
CPC分类号： G01N33/5011 , C12Q1/6881 , C12Q1/6886 , C12Q2600/106 , G01N2800/52
摘要： The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide capable of detecting rearrangements in the NUT gene are provided.
摘要翻译：本发明涉及一种选择（a）对选择性CDK9抑制剂具有易感性的细胞，（a）组织或（a）细胞培养物的方法。本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用选择性CDK9抑制剂进行治疗的反应性的方法。特别地，本发明提供了用于鉴定对选择性CDK9抑制剂敏感的患者或患者的体外方法，由此患者怀疑患有NUT中线癌（NMC）。本发明还涉及监测或预测NUT中线癌（NMC）治疗功效的方法，其中特别设想用选择性CDK9抑制剂进行治疗。还描述了在NUT基因中具有至少一个重排的（转基因）非人动物或（转基因）细胞用于筛选和/或验证用于治疗NUT中线癌（NMC）的药物的用途。此外，提供了可用于实施本文所述方法的试剂盒以及能够检测NUT基因重排的寡核苷酸或多核苷酸。

4. 发明申请

US20150329537A2 CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA 审中-公开
标题翻译： CDK9抑制剂治疗中性粒细胞减少症
公开(公告)号：US20150329537A2
公开(公告)日：2015-11-19
申请号：US14240329
申请日：2012-08-22
申请人： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
发明人： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
IPC分类号： C07D471/04 , C07D405/10 , C07D401/12 , C07D403/04 , C07D403/12 , C07C53/18 , C07D213/40 , C07D251/16 , C07D401/04
CPC分类号： C07C53/18 , A61K31/4418 , A61K31/53 , C07D213/40 , C07D213/74 , C07D251/16 , C07D251/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/10 , C07D471/04
摘要： The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
摘要翻译：本发明涉及用于治疗，改善和/或预防中线癌症的CDK9抑制剂，特别是选择性CDK9抑制剂。用于治疗，预防或改善中线癌的相应方法也是本发明的主题。优选地，根据本发明，用CDK9抑制剂处理NUT中线癌。

5. 发明申请

US20140303167A1 CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA 审中-公开
标题翻译： CDK9抑制剂治疗中性粒细胞减少症
公开(公告)号：US20140303167A1
公开(公告)日：2014-10-09
申请号：US14240329
申请日：2012-08-22
申请人： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
发明人： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
IPC分类号： C07D471/04 , C07D405/10 , C07D401/12 , C07D403/04 , C07D403/12 , C07C53/18 , C07D213/40 , C07D251/16 , C07D401/04
CPC分类号： C07C53/18 , A61K31/4418 , A61K31/53 , C07D213/40 , C07D213/74 , C07D251/16 , C07D251/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/10 , C07D471/04
摘要： The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
摘要翻译：本发明涉及用于治疗，改善和/或预防中线癌症的CDK9抑制剂，特别是选择性CDK9抑制剂。用于治疗，预防或改善中线癌的相应方法也是本发明的主题。优选地，根据本发明，用CDK9抑制剂处理NUT中线癌。

6. 发明授权

US06849409B2 Cellular kinases involved in Cytomegalovirus infection and their inhibition 失效
标题翻译：细胞激酶参与巨细胞病毒感染及其抑制
公开(公告)号：US06849409B2
公开(公告)日：2005-02-01
申请号：US09981397
申请日：2001-10-16
申请人： Daniel Schubart , Peter Habenberger , Matthias Stein-Gerlach , Dorian Bevec
发明人： Daniel Schubart , Peter Habenberger , Matthias Stein-Gerlach , Dorian Bevec
IPC分类号： A61K31/00 , A61K31/352 , A61K31/404 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/517 , A61K31/519 , A61K31/5377 , C12Q1/18 , C12Q1/48 , G01N33/569 , C12Q1/68
CPC分类号： C12Q1/18 , A61K31/00 , A61K31/352 , A61K31/404 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/517 , A61K31/519 , A61K31/5377 , C12Q1/485 , G01N33/56994
摘要： The role of certain cellular kinases active during Human Cytomegalovirus infection is disclosed. These cellular kinases are useful to detect HCMV infection, and can be used to screen for cellular kinase inhibitors. Cellular kinases inhibitors, which effectively downregulate these key cellular components, serve as effective therapeutics against HCMV infection.
摘要翻译：公开了在人巨细胞病毒感染期间活性的某些细胞激酶的作用。这些细胞激酶可用于检测HCMV感染，并可用于筛选细胞激酶抑制剂。细胞激酶抑制剂，其有效地下调这些关键的细胞组分，作为对HCMV感染的有效治疗剂。

7. 发明授权

US06623951B1 HBV vectors and cells for producing the same 失效
标题翻译： HBV载体和产生相同的细胞
公开(公告)号：US06623951B1
公开(公告)日：2003-09-23
申请号：US08952674
申请日：1998-03-02
申请人： Peter Hofschneider , Peter Habenberger , Ludwig Weiss
发明人： Peter Hofschneider , Peter Habenberger , Ludwig Weiss
IPC分类号： C12N1500
CPC分类号： C07K14/005 , A61K48/00 , C12N15/86 , C12N2730/10122 , C12N2730/10143
摘要： This invention relates to an HBV vector in which functional genes of HBV are at least partially deleted. In addition, this invention concerns a process for producing such an HBV vector as well as cells usable for this purpose.
摘要翻译：本发明涉及其中HBV的功能基因至少部分缺失的HBV载体。此外，本发明涉及生产这种HBV载体的方法以及可用于此目的的细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式